Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer’s Disease Patients and Controls after Correction for Ventricular Volumes

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Alzheimer's Disease

• Publication date

  2017-01-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.3233/JAD-160668PMID 28059783
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia.

  2016cited by this paper
• Application of the IWG-2 Diagnostic Criteria for Alzheimer’s Disease to the ADNI

  2016cited by this paper
• Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

  2015cited by this paper
• Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease

  2015cited by this paper
• Cognition, Brain Atrophy, and Cerebrospinal Fluid Biomarkers Changes from Preclinical to Dementia Stage of Alzheimer's Disease and the Influence of Apolipoprotein E

  2015cited by this paper
• PET/MR in dementia and other neurodegenerative diseases.

  2015cited by this paper
• Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration

  2014cited by this paper
• The AD-CSF-Index Discriminates Alzheimer's Disease Patients from Healthy Controls: A Validation Study

  2013cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders (DSM).

  2013cited by this paper
• Imaging of the entire cerebrospinal fluid volume with a multistation 3D SPACE MR sequence: feasibility study in patients with hydrocephalus

  2013cited by this paper
• Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

  2012cited by this paper
• Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.

  2012cited by this paper
• Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer’s Disease

  2012cited by this paper
• Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

  2012cited by this paper
• Una nueva aproximación en el diagnóstico de la enfermedad de Alzheimer con biomarcadores: descripción del AD-CSF-Index

  2012cited by this paper
• Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates

  2012cited by this paper
• [A new approach to the Alzheimer's disease diagnosis with biomarkers: description of the AD-CSF-Index].

  2012cited by this paper
• Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

  2011cited by this paper
• A comprehensive testing protocol for MRI neuroanatomical segmentation techniques: Evaluation of a novel lateral ventricle segmentation method

  2011influential reference
• Alzheimer's disease.

  2011cited by this paper
• The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Brain Ventricular Volume and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease

  2010cited by this paper
• Revising the definition of Alzheimer's disease: a new lexicon.

  2010cited by this paper
• Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid

  2010cited by this paper
• The use of PET in Alzheimer disease

  2010cited by this paper
• Serial MRI and CSF biomarkers in normal aging, MCI, and AD

  2010cited by this paper
• Hippocampal atrophy rates in Alzheimer disease

  2009cited by this paper
• Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls

  2009cited by this paper
• Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly

  2009cited by this paper
• Multiplicity of cerebrospinal fluid functions: New challenges in health and disease

  2008cited by this paper
• Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature

  2008cited by this paper
• Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database.

  2008cited by this paper
• Cerebral Ventricular Changes Associated With Transitions Between Normal Cognitive Function, Mild Cognitive Impairment, and Dementia

  2007cited by this paper
• Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

  2007cited by this paper
• Alzheimer's disease

  2006cited by this paper
• アルツハイマー病の早期診断に向けて-米国 Alzheimer's Disease Neuroimaging Initiative の取り組み

  2006cited by this paper
• Mild cognitive impairment as a diagnostic entity

  2004cited by this paper
• Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

  2003cited by this paper
• Mild Cognitive Impairment Clinical Characterization and Outcome

  1999cited by this paper
• Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.

  1999cited by this paper
• Frontotemporal lobar degeneration

  1998cited by this paper
• Literature

  1994cited by this paper
• Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.

  1992cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper

• CSF levels of brain-derived proteins correlate with brain ventricular volume in cognitively healthy 70-year-olds

  2024cites this paper
• The genetic regulation of protein expression in cerebrospinal fluid

  2022cites this paper
• Brain ventricles, CSF and cognition: a narrative review

  2022cites this paper
• Ventricular volume in relation to lumbar CSF levels of amyloid-β 1–42, tau and phosphorylated tau in iNPH, is there a dilution effect?

  2022cites this paper
• White Matter Hyperintensities Are No Major Confounder for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers

  2020influential citation
• Choroid plexus volume is associated with levels of CSF proteins: relevance for Alzheimer's and Parkinson's disease.

  2020cites this paper
• Altered Expression of Long Non-coding RNAs in Peripheral Blood Mononuclear Cells of Patients with Alzheimer’s Disease

  2020cites this paper
• Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease

  2019cites this paper
• Active Aging and Disease Management

  2019cites this paper
• The Quadruple Helix-Based Innovation Model of Reference Sites for Active and Healthy Ageing in Europe: The Ageing@Coimbra Case Study

  2018cites this paper
• Ventricular and Periventricular Anomalies in the Aging and Cognitively Impaired Brain

  2018cites this paper
• Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer’s disease

  2017cites this paper